Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
NAD+ modulator (investigational)

KL1333 (napazimone)

An investigational treatment for Primary mitochondrial disease (mitochondrial DNA).

Phase 2by Pharming
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify KL1333 (napazimone) wherever you encounter it, plus the key facts at a glance.

Generic name
KL1333 (napazimone)
Development codes
KL1333, napazimone
Drug class
NAD+ modulator (investigational)
Manufacturer
Pharming
How it's taken
In the Phase 2 trial, KL1333 or placebo is taken by mouth twice a day, with the dose adjusted during the study (a flexible-dose design).

An oral drug taken twice a day, in a Phase 2 trial for adults with primary mitochondrial disease caused by mitochondrial DNA changes, including MELAS, MIDD, Kearns-Sayre and MERRF.

Not approved anywhere, and not being tested in children; the trial excludes Leigh syndrome.

How KL1333 (napazimone) works

NAD+ and NADH are helper molecules that mitochondria use at several steps of energy production. Pharming describes KL1333 as correcting the balance between them so that the remaining working mitochondria produce more energy. It does not correct the underlying gene fault.

Clinical trial results

FALCON (NCT05650229) is a Phase 2, randomized, double-blind, placebo-controlled, adaptive trial that began in December 2022 and plans to enroll about 180 adults with a genetically confirmed mitochondrial DNA disease and chronic fatigue. The main outcomes are a fatigue questionnaire (PROMIS Fatigue) and the 30-second sit-to-stand test.

ClinicalTrials.gov still lists primary completion in October 2027, but Pharming said on October 22, 2026 that it expects about 145 of the 180 participants enrolled by the end of 2026 and enrollment to finish in the first half of 2027. Sites are in the United States, Australia and 9 European countries. An open-label extension (NCT07514338) lets participants continue on the drug.

Main registered trial: NCT05650229 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.

Side effects and safety

Early trial safety observations

Safety results from the Phase 2 FALCON trial have not been published. The trial is placebo-controlled with a flexible dose, so side effects will be reported against placebo when it reads out, which Pharming expects about 1 year after enrollment finishes in the first half of 2027. The only published safety data come from a Phase 1a/1b study in the UK that gave KL1333 or placebo to healthy volunteers and to 8 adults with mitochondrial disease, for up to 10 days[4].

No one had a serious adverse event, and no one stopped because of a side effect. Stomach and gut problems were the most common side effects and became more common at higher doses. In healthy volunteers, 250mg once a day was poorly tolerated because of belly pain and diarrhea, and splitting a 150mg daily dose into 2 or 3 smaller doses eased those effects.

Of the 6 adults with mitochondrial disease who took KL1333 at 50mg once a day, while 2 others got placebo, 4 had mild gut side effects, with 1 episode of bloating, 1 of diarrhea and 2 of nausea reported[4]. FALCON adjusts the dose during the trial, and the study team can say what is known about side effects at the doses it uses.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking KL1333 (napazimone)

In the Phase 2 trial, KL1333 or placebo is taken by mouth twice a day, with the dose adjusted during the study (a flexible-dose design).

Development history

Pharming Technologies B.V. sponsors the FALCON Phase 2 trial, which began in December 2022, and the open-label extension that follows it.

Ask anything about KL1333 (napazimone)
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Primary mitochondrial disease (mitochondrial DNA) trials

Common questions about KL1333 (napazimone)

▸What is KL1333 (napazimone)?

An oral drug taken twice a day, in a Phase 2 trial for adults with primary mitochondrial disease caused by mitochondrial DNA changes, including MELAS, MIDD, Kearns-Sayre and MERRF. Not approved anywhere, and not being tested in children; the trial excludes Leigh syndrome.

▸How does KL1333 (napazimone) work?

NAD+ and NADH are helper molecules that mitochondria use at several steps of energy production. Pharming describes KL1333 as correcting the balance between them so that the remaining working mitochondria produce more energy. It does not correct the underlying gene fault.

▸What are the side effects of KL1333 (napazimone)?

Safety results from the Phase 2 FALCON trial have not been published. The trial is placebo-controlled with a flexible dose, so side effects will be reported against placebo when it reads out, which Pharming expects about 1 year after enrollment finishes in the first half of 2027. The only published safety data come from a Phase 1a/1b study in the UK that gave KL1333 or placebo to healthy volunteers and to 8 adults with mitochondrial disease, for up to 10 days[4]. No one had a serious adverse event, and no one stopped because of a side effect. Stomach and gut problems were the most common side effects and became more common at higher doses. In healthy volunteers, 250mg once a day was poorly tolerated because of belly pain and diarrhea, and splitting a 150mg daily dose into 2 or 3 smaller doses eased those effects. Of the 6 adults with mitochondrial disease who took KL1333 at 50mg once a day, while 2 others got placebo, 4 had mild gut side effects, with 1 episode of bloating, 1 of diarrhea and 2 of nausea reported[4]. FALCON adjusts the dose during the trial, and the study team can say what is known about side effects at the doses it uses.

▸How is KL1333 (napazimone) taken?

In the Phase 2 trial, KL1333 or placebo is taken by mouth twice a day, with the dose adjusted during the study (a flexible-dose design).

▸Is KL1333 (napazimone) FDA approved?

KL1333 (napazimone) is currently in phase 2 clinical trials for Primary mitochondrial disease (mitochondrial DNA). It has not yet received FDA approval.

▸Is KL1333 being tested for Leigh syndrome?

No. The FALCON trial enrolls adults with mitochondrial DNA diseases such as MELAS, Kearns-Sayre and MERRF who have chronic fatigue, and it specifically excludes Leigh syndrome from any gene, as well as NARP and LHON. Children are not eligible. Pharming said on October 22, 2026 that it now expects enrollment to finish in the first half of 2027, with topline results about 1 year after that. [1]

▸Where is the KL1333 trial recruiting?

FALCON (NCT05650229) lists sites in the United States, Australia, Belgium, Czechia, Denmark, France, Germany, Italy, the Netherlands, Spain and the United Kingdom, and was recruiting as of September 2026. The ClinicalTrials.gov listing has the current sites. [2]

▸Is KL1333 FDA approved?

No. KL1333 is not FDA-approved and is not approved anywhere. It is in a Phase 2 trial called FALCON (NCT05650229), sponsored by Pharming, which began in December 2022 and plans to enroll about 180 adults with a genetically confirmed mitochondrial DNA disease and chronic fatigue. Pharming expects enrollment to finish in the first half of 2027 and topline results about 1 year later, and an open-label extension (NCT07514338) lets participants continue on the drug. [2][3]

▸How does KL1333 work?

KL1333 is an oral drug taken by mouth twice a day, with the dose adjusted during the FALCON trial in a flexible-dose design. Pharming describes it as correcting the balance between NAD+ and NADH, helper molecules that mitochondria use at several steps of energy production, so the remaining working mitochondria produce more energy. It does not correct the underlying gene fault. [2]

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Pharming Group · 2026-10-22. Pharming Group announces third quarter 2026 revenues above market expectations. https://www.pharming.com/our-news/pharming-group-announces-third-quarter-2026-revenues-above-market-expectations
  2. ClinicalTrials.gov. Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease. https://clinicaltrials.gov/study/NCT05650229
  3. ClinicalTrials.gov. KL1333 open-label extension study. https://clinicaltrials.gov/study/NCT07514338
  4. Brain · 2025-01-07. Optimizing rare disorder trials: a phase 1a/1b randomized study of KL1333 in adults with mitochondrial disease. https://pmc.ncbi.nlm.nih.gov/articles/PMC11706290/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow KL1333 (napazimone) by email

We'll email you when the FDA acts on KL1333 (napazimone) and when new trials for the condition you pick open. Unsubscribe anytime.

You'll get:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site